Maxalt-mlt and Duragesic drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Maxalt-mlt (rizatriptan benzoate) and Duragesic (fentanyl). Common drug interactions include sleep disorder among females and brain injury among males.

The phase IV clinical study analyzes what interactions people have when they take Maxalt-mlt and Duragesic. It is created by eHealthMe based on reports of 43 people who take the same drugs from the FDA, and is updated regularly.

What is Maxalt-mlt?

Maxalt-mlt has active ingredients of rizatriptan benzoate. It is often used in migraine. eHealthMe is studying from 1,534 Maxalt-mlt users. Check the latest studies of Maxalt-mlt.

What is Duragesic?

Duragesic has active ingredients of fentanyl. eHealthMe is studying from 66,597 Duragesic users. Check the latest studies of Duragesic.



On Jul, 12, 2026

43 people who take Maxalt-mlt and Duragesic together, and have interactions are studied.

Maxalt-mlt and Duragesic drug interactions.

What are the common drug interactions of Maxalt-Mlt and Duragesic, by gender? *:

female:

  1. Sleep disorder
  2. Spinal osteoarthritis (joint cartilage loss in spine)
  3. Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
  4. Disturbance in attention
  5. Gallbladder polyp (growths or lesions resembling growths (polypoid lesions) in the wall of the gallbladder)
  6. Mobility decreased (ability to move is reduced)
  7. Stomatitis (inflammation of mucous membrane of mouth)
  8. Surgery
  9. Tooth extraction
  10. Wound

male:

  1. Brain injury
  2. Conversion disorder (neurological symptoms, such as numbness, blindness, paralysis, or fits without a definable organic cause)
  3. Fall
  4. Gun shot wound
  5. Haemorrhage (bleeding)
  6. Headache (pain in head)
  7. Hyperbilirubinaemia (excess of bilirubin in the blood)
  8. Multi-organ disorder (multiple organ disease)
  9. Multiple sclerosis relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath)
  10. Petechiae (a small red or purple spot caused by bleeding into the skin)

What are the common drug interactions of Maxalt-Mlt and Duragesic, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Brain injury
  2. Conversion disorder (neurological symptoms, such as numbness, blindness, paralysis, or fits without a definable organic cause)
  3. Depression
  4. Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
  5. Paralysis
  6. Chronic kidney disease
  7. Epistaxis (bleed from the nose)
  8. Headache (pain in head)

50-59:

  1. Fall
  2. Multiple sclerosis relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath)
  3. Hypoaesthesia oral (reduced sense of touch or sensation in mouth)
  4. Nausea (feeling of having an urge to vomit)
  5. Vomiting
  6. Asthenia (weakness)
  7. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  8. Abdominal pain
  9. Accident at work
  10. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)

60+:

  1. Drug ineffective
  2. Drug hypersensitivity
  3. Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells)
  4. Respiratory failure (inadequate gas exchange by the respiratory system)
  5. Urinary tract infection
  6. Pruritus (severe itching of the skin)
  7. Bile duct obstruction (blockage in the tubes that carry bile from the liver to the gallbladder)
  8. Bladder dysfunction
  9. Fall
  10. Hyperbilirubinaemia (excess of bilirubin in the blood)

What are the existing conditions these people have? *

  1. Breast Cancer Metastatic: 24 people, 55.81%
  2. Hot Flush (sudden feelings of heat): 21 people, 48.84%
  3. Discomfort: 21 people, 48.84%
  4. Breast Cancer: 21 people, 48.84%
  5. Ovarian Cancer (cancer of ovary): 21 people, 48.84%
  6. Neoplasm Malignant (cancer tumour): 21 people, 48.84%
  7. Granulocyte Count Decreased: 20 people, 46.51%
  8. Pain: 20 people, 46.51%
  9. Stress And Anxiety: 14 people, 32.56%
  10. Restless Leg Syndrome (a powerful urge to move your legs): 12 people, 27.91%

* Approximation only. Some reports may have incomplete information.

Do you take Maxalt-mlt and Duragesic?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Maxalt-mlt and Duragesic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Maxalt-mlt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Duragesic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Maxalt-mlt and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Duragesic and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on rizatriptan benzoate and fentanyl (the active ingredients of Maxalt-mlt and Duragesic, respectively), and Maxalt-mlt and Duragesic (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: